Experimental combo targets Hard-to-Treat lung cancer mutations
NCT ID NCT05704634
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tests whether combining two drugs—sarilumab (Kevzara) and cemiplimab—can safely control non-small cell lung cancer with specific gene changes (EGFR or LKB1/STK11 mutations). About 56 adults with advanced disease will receive the combination. The main goal is to check for side effects and see if the tumors shrink or stop growing.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a simple CT scan catch lung cancer earlier in kuwait?
- Can a new immunotherapy combo outsmart advanced lung cancer?
- Can a new drug combo revive Immunotherapy's power against resistant tumors?
- Double attack on mutant KRAS: can two targeted drugs outsmart resistant cancers?
- Seeing the fight: new imaging tracer may reveal how immune cells attack lung cancer
- Could a bronchial wash detect lung cancer mutations faster?